Kura Oncology Stock News

Kura Oncology (KURA) said the U.S. Food and Drug Administration ((FDA)) lifted the partial clinical hold on the KOMET-001 phase 1b study of KO-539 in patients with relapsed or

FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome KOMET-001 study to resume screening and enrollment of new patients Encouraging safety, tolerability and clinical activity observed among patients on study SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA ), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The partial clinical hold was lifted following agreement with the FDA on the Company''s mitigation strategy for differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML. "I am very proud of our team for working diligently with the FDA and site investigators to resolve the partial clinical hold in such a timely manner," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "Activities to resume patient screening are underway, and we look forward to expediting enrollment of patients in the Phase 1b study and determining the recommended Phase 2 dose for KO-539 in the coming months.

Kura Oncology (NASDAQ:KURA)s stock had its buy rating reiterated by equities research analysts at JMP Securities in a research note issued on Wednesday, TipRanks reports. They presently have a $26.00 target price on the stock. JMP Securities price objective points to a potential upside of 110.70% from the companys previous close. Other equities research analysts []

The stock price of Kura Oncology Inc (NASDAQ: KURA) increased by 4.75% in the most recent trading session. This is why it happened.

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of Buy from the seven ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have []

Shares of Kura Oncology, Inc. (NASDAQ:KURA) gapped down before the market opened on Thursday . The stock had previously closed at $13.35, but opened at $12.75. Kura Oncology shares last traded at $13.57, with a volume of 1,825 shares trading hands. A number of research firms have recently issued reports on KURA. JMP Securities restated []

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Credit Suisse Group from $40.00 to $21.00 in a research report released on Friday morning, The Fly reports. The brokerage currently has an outperform rating on the stock. A number of other equities analysts have also issued reports on the stock. Wedbush reiterated an outperform rating []

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Credit Suisse Group from $40.00 to $21.00 in a research report released on Friday, The Fly reports. The firm currently has an outperform rating on the stock. Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded Kura Oncology from []

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kura Oncology, Inc. (Kura or the Company) (NASDAQ: KURA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Incs (NASDAQ:

Shares of Kura Oncology, Inc. (NASDAQ:KURA) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $11.90 and last traded at $13.26, with a volume of 85180 shares changing hands. The stock had previously closed at $16.60. Several equities analysts have recently issued reports on the company. Wedbush […]

A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.